Phil

What Phil does

Phil (PHIL Inc.) is a private, Scottsdale-headquartered pharmaceutical commercialization software company founded in 2015 that sells an integrated medication access platform to pharma manufacturers — primarily retail and specialty-lite brands. The platform combines two complementary modules: PHIL Core, a digital hub that handles prior authorization (including a proprietary "1-click PA" process), benefits verification, and HCP engagement; and PHIL Direct (Direct-to-Patient 2.0), launched in September 2025, which layers brand-controlled intake, telemedicine, flexible coverage/cash/hybrid routing, and eCommerce-style fulfillment on top of the core. Underlying these modules is a 50-state integrated pharmacy network with reported 99%+ plan coverage, an in-house cash pharmacy operated through subsidiary PHILRx, LLC (locations in Scottsdale, AZ and Columbus, OH, NPI 1487163598), a wholesale distribution arm, and an AI-supported data layer surfacing 120+ real-time script-level data points.

The platform is HIPAA- and AICPA SOC-compliant, SMS-based for app-free enrollment, and supports 120+ languages. PHIL serves three distinct user groups: pharma manufacturers (the enterprise paying customer, addressed via a consultative sales-led motion with custom multi-year contracts and a supporting GTN Calculator tool), patients (end users of prescriptions, served free of charge via PHILRx with lifetime free delivery), and healthcare providers (prescribers who e-prescribe through PHILRx via EMR pharmacy directories). Revenue is generated through enterprise partnerships with pharma brands, with programs combining PHIL Core and PHIL Direct in configurable coverage-first, cash-pay, or hybrid models. Pricing is not publicly disclosed; demos are booked on a quote basis.

The company has raised $56M in Series D equity (June 2021, led by Warburg Pincus, with potential up to $100M) and $60M of growth debt from K2 HealthVentures (July 2025) earmarked specifically for AI integration and therapeutic-area expansion. The company has stated it reached cash flow positive status following the 2021 Series D, and reports 150% year-over-year net revenue growth in 2024 alongside 10x prescription volume growth since 2021.

Name

Phil

Legal name

PHIL Inc.

Website

https://phil.us

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Phil (PHIL Inc.) sells an integrated digital hub and direct-to-patient platform that helps retail and specialty-lite pharma brands maximize prescription starts, coverage, adherence, and gross-to-net, serving manufacturers as enterprise customers while operating its own 50-state pharmacy network and in-house PHILRx pharmacy for patients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Access Software

NAICS

Pharmacies and Drug Retailers (456110), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Virtual Pharmacy & Medication Management Integration Platforms (HLALABAL)

akta.pro secondary industries

Pharmacy Benefit Management (PBM) & Pharmacy Network Administration (HLAFALAI), Pharmacy-Integrated Virtual Care & ePrescribing (Employer Benefit) (HLALADAH)

Keywords

• Pharmaceutical access platform
• Prescription access software
• Prior authorization technology
• Direct-to-patient platform
• Medication adherence platform

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharma Manufacturer Subscription/Partnership Programs: PHIL generates revenue through commercial partnerships with pharma manufacturers (retail and specialty-lite brands), providing access programs combining the PHIL Core digital hub and PHIL Direct DTP platform. Programs are customized to each brand's needs with flexible intake, coverage, cash-pay, and hybrid models. Pricing is not publicly disclosed; demos are booked on a consultative basis.
2. Growth Debt Financing (Capital Markets): PHIL secured $60 million in growth capital from K2 HealthVentures in July 2025 to accelerate AI integration, supplementing its Series D equity funding of $56 million raised in 2021 (with potential investment up to $100 million from Warburg Pincus). Revenue stream supplemented by growth debt financing.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

PHIL operates a software-driven pharmaceutical commercialization platform that combines a digital hub (PHIL Core) for prior authorization, benefits verification, and patient/HCP engagement with a Direct-to-Patient 2.0 layer (PHIL Direct) for intake, telemedicine, coverage/cash-pay routing, and fulfillment. The platform is delivered to pharma manufacturers as an alternative access channel, supported by a 50-state integrated pharmacy network, an in-house cash pharmacy (PHILRx), a wholesale distribution arm, and AI-powered data and insights. Programs are customized per brand with Coverage-First, Cash-Pay, or Hybrid routing models.

Product overview

PHIL offers a single integrated medication access platform built from two complementary sub-products — PHIL Core (the digital hub that handles prior authorization, benefits verification, and patient/HCP engagement) and PHIL Direct (the Direct-to-Patient 2.0 layer that adds intake, telemedicine, flexible routing, and brand-led eCommerce-style fulfillment) — served by an underlying dispense network, an in-house cash pharmacy (PHILRx, with locations in OH and AZ), a wholesale distribution arm, and an AI-powered data and insights layer. The platform is delivered to pharma manufacturers (especially retail and specialty-lite brands) as an alternative access channel and is configured per brand, with the GTN Calculator available as a supporting tool.

Differentiator

Problem solved

Functional benefit

Brands

• PHILRx: In-house and contracted retail pharmacy service used by patients, providers, and prescribers for affordable prescription fulfillment with free home delivery.
• PHIL Core
• PHIL Direct

Products and services

• PHIL Platform Unified all-in-one medication access platform combining PHIL Core (digital hub) and PHIL Direct (direct-to-patient 2.0), plus integrated pharmacy network, wholesale arm, in-house cash pharmacy, and data & insights layer, designed to maximize starts, coverage, adherence, and commercial performance for retail and specialty-lite pharma brands.
• PHIL Core Technology-driven digital hub delivering a seamless medication access experience, proprietary 1-click prior authorization and benefits verification, and integrated 50-state pharmacy network; includes a Patient Support Team, HCP Engagement Team, and real-time Data & Insights dashboards for pharma manufacturers.
• PHIL Direct Direct-to-Patient 2.0 solution that creates an eCommerce-like patient access journey, integrating brand marketing assets, intake (in-person HCP, telemedicine, Rx transfer), routing (coverage/cash/hybrid), and fulfillment (wholesale arm, in-house cash pharmacy, dispense network) into one configurable program for pharma manufacturers.
• PHILRx PHIL's patient-facing pharmacy service delivering prescription medications via free home delivery with SMS enrollment, benefits verification, prior authorization support, copay assistance, and refill reminders; operates in-house cash pharmacies in Columbus, OH and Scottsdale, AZ and integrates with a 50-state partner network with 99%+ plan coverage.

Quantifiable outcome

• 2x+ patient starts vs. traditional channels
• +11 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• Digital Medicine Society (DiMe)coreGTM or Marketing Partner · 16 April 2026PHIL Inc. is a founding partner of the Digital Medicine Society's (DiMe) pre-competitive initiative 'Optimizing Direct-to-Patient (DTP) Strategies for Pharma.' The coalition brings together founding partners across the healthcare ecosystem including Wheel, Welldoc, Ypsomed, and others to co-create a practical blueprint ensuring DTP models operate safely and earn patient trust. The initiative maps the regulatory landscape, develops guidance for self-pay models, and defines metrics for patient access and affordability.
• Tenpoint Therapeutics LtdflagshipStrategic or Co-development Partner · 2 April 2026Tenpoint Therapeutics and PHIL partnered to launch a Direct-to-Patient cash program for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia. The program addresses high out-of-pocket costs and access barriers for approximately 128 million Americans and 2 billion people worldwide affected by presbyopia. It offers transparent pricing, home delivery, and dedicated support to address affordability barriers and support long-term patient adherence. This is a featured partnership prominently displayed across PHIL's website.
• Sprout PharmaceuticalsflagshipStrategic or Co-development PartnerSprout Pharmaceuticals and PHIL expanded their Affordable Direct-to-Patient Access Program for Addyi (flibanserin), an innovative women's health brand. The partnership delivers affordable access for patients and has been featured prominently in PHIL's announcements. Achieved 5x first fills per patient and 90%+ dispense coverage as a result.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alto Pharmacy: Tech-enabled retail and specialty-lite mail-order pharmacy offering app-based enrollment, free same-day delivery, PA support, and cash-pay programs, directly overlapping with Phil's PHILRx and DTP 2.0 value proposition for branded retail and specialty-lite therapies.
• Capsule Pharmacy: Consumer-grade digital pharmacy with same-day delivery, in-app PA and benefits support, and a focus on branded retail medications; competes head-to-head with Phil's patient-facing pharmacy and DTP experience.
• Truepill: API-first pharmacy and telehealth infrastructure platform powering DTP cash-pay and brand-led programs for pharma and consumer health companies, comparable to Phil's technology stack and pharma manufacturer DTP offering.

Broad incumbents

• Amazon Pharmacy: Amazon-owned online pharmacy offering home delivery, transparent pricing, and integrated Prime experiences; a dominant incumbent in retail DTP that competes on convenience and scale, increasingly moving into branded specialty and cash-pay programs relevant to Phil's customer base.
• EVERSANA: Large pharma commercialization services platform offering hub services, patient services, PA and access support, and specialty distribution; directly comparable to Phil's hub-and-DTP offering as a broader incumbent serving pharma manufacturers.
• CoverMyMeds (McKesson): McKesson-owned electronic prior authorization, benefits verification, and patient access network widely used across U.S. pharma; overlaps with Phil's 1-click PA workflow and hub services from an established incumbent perspective.
• Optum Specialty Pharmacy (UnitedHealth Group): One of the largest U.S. specialty pharmacy and patient access operations, embedded within UnitedHealth's payer-PBM-provider stack; competes with Phil for branded and specialty-lite brand access, adherence, and hub services at scale.
• Walgreens Specialty Pharmacy: National retail and specialty pharmacy chain with centralized specialty operations, hub services, and home delivery, providing an established incumbent alternative for pharma manufacturers evaluating access partners like Phil.

Emerging players

• Hims & Hers Health: Consumer telehealth and DTP platform for branded and generic therapies with its own pharmacy fulfillment; increasingly relevant as a buyer of pharma brand partnerships and as a competitive consumer DTP channel overlapping with Phil's PHIL Direct 2.0 model.
• Ro: Vertical telehealth and pharmacy platform operating its own DTP and cash-pay programs across multiple therapeutic areas; competes with Phil for branded pharma manufacturer DTP partnerships and consumer-grade patient access experiences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/phil-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phil